

## TRADEMARK ASSIGNMENT COVER SHEET

Electronic Version v1.1  
Stylesheet Version v1.2

ETAS ID: TM847880

<b>SUBMISSION TYPE:</b>	NEW ASSIGNMENT		
<b>NATURE OF CONVEYANCE:</b>	ASSIGNMENT OF THE ENTIRE INTEREST AND THE GOODWILL		
<b>CONVEYING PARTY DATA</b>			
<b>Name</b>	<b>Formerly</b>	<b>Execution Date</b>	<b>Entity Type</b>
Novartis AG		09/29/2023	Company: SWITZERLAND
<b>RECEIVING PARTY DATA</b>			
<b>Name:</b>	Bausch + Lomb Ireland Limited		
<b>Street Address:</b>	3013 Lake Drive		
<b>Internal Address:</b>	Citywest Business Campus		
<b>City:</b>	Dublin		
<b>State/Country:</b>	IRELAND		
<b>Postal Code:</b>	D24 PPT3		
<b>Entity Type:</b>	Private Company Limited by Shares: IRELAND		
<b>PROPERTY NUMBERS Total: 9</b>			
<b>Property Type</b>	<b>Number</b>	<b>Word Mark</b>	
<b>Serial Number:</b>	97817022	II	
<b>Serial Number:</b>	90028312	INFLAMMATION	
<b>Serial Number:</b>	97564942	FLAMM	
<b>Serial Number:</b>	97564946	INFLAMMATION	
<b>Serial Number:</b>	90022578	NOT TODAY, DRY EYE SCRATCH	
<b>Serial Number:</b>	90028338	INFLAMMATION	
<b>Registration Number:</b>	5050074	XIIDRA	
<b>Registration Number:</b>	5271076	XIIDRA	
<b>Registration Number:</b>	7006718	NOT TODAY, DRY EYE	
<b>CORRESPONDENCE DATA</b>			
<b>Fax Number:</b>			
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>			
<b>Phone:</b>	848-310-2069		
<b>Email:</b>	trademarks@bausch.com		
<b>Correspondent Name:</b>	Nancy L. Rowe		
<b>Address Line 1:</b>	400 Somerset Corp. Blvd.		
<b>Address Line 4:</b>	Bridgewater, NEW JERSEY 08807		

CH \$240.00 97817022

**DOMESTIC REPRESENTATIVE**

**Name:** Nancy L. Rowe  
**Address Line 1:** 400 Somerset Corp. Blvd.  
**Address Line 2:** Law Department  
**Address Line 4:** Bridgewater, NEW JERSEY 08807

**NAME OF SUBMITTER:** Holly M. Smith

**SIGNATURE:** /Holly M. Smith/

**DATE SIGNED:** 10/23/2023

**Total Attachments: 56**

source=Project Symphony - Trademark Assignment Agreement [Executed]#page1.tif  
source=Project Symphony - Trademark Assignment Agreement [Executed]#page2.tif  
source=Project Symphony - Trademark Assignment Agreement [Executed]#page3.tif  
source=Project Symphony - Trademark Assignment Agreement [Executed]#page4.tif  
source=Project Symphony - Trademark Assignment Agreement [Executed]#page5.tif  
source=Project Symphony - Trademark Assignment Agreement [Executed]#page6.tif  
source=Project Symphony - Trademark Assignment Agreement [Executed]#page7.tif  
source=Project Symphony - Trademark Assignment Agreement [Executed]#page8.tif  
source=Project Symphony - Trademark Assignment Agreement [Executed]#page9.tif  
source=Project Symphony - Trademark Assignment Agreement [Executed]#page10.tif  
source=Project Symphony - Trademark Assignment Agreement [Executed]#page11.tif  
source=Project Symphony - Trademark Assignment Agreement [Executed]#page12.tif  
source=Project Symphony - Trademark Assignment Agreement [Executed]#page13.tif  
source=Project Symphony - Trademark Assignment Agreement [Executed]#page14.tif  
source=Project Symphony - Trademark Assignment Agreement [Executed]#page15.tif  
source=Project Symphony - Trademark Assignment Agreement [Executed]#page16.tif  
source=Project Symphony - Trademark Assignment Agreement [Executed]#page17.tif  
source=Project Symphony - Trademark Assignment Agreement [Executed]#page18.tif  
source=Project Symphony - Trademark Assignment Agreement [Executed]#page19.tif  
source=Project Symphony - Trademark Assignment Agreement [Executed]#page20.tif  
source=Project Symphony - Trademark Assignment Agreement [Executed]#page21.tif  
source=Project Symphony - Trademark Assignment Agreement [Executed]#page22.tif  
source=Project Symphony - Trademark Assignment Agreement [Executed]#page23.tif  
source=Project Symphony - Trademark Assignment Agreement [Executed]#page24.tif  
source=Project Symphony - Trademark Assignment Agreement [Executed]#page25.tif  
source=Project Symphony - Trademark Assignment Agreement [Executed]#page26.tif  
source=Project Symphony - Trademark Assignment Agreement [Executed]#page27.tif  
source=Project Symphony - Trademark Assignment Agreement [Executed]#page28.tif  
source=Project Symphony - Trademark Assignment Agreement [Executed]#page29.tif  
source=Project Symphony - Trademark Assignment Agreement [Executed]#page30.tif  
source=Project Symphony - Trademark Assignment Agreement [Executed]#page31.tif  
source=Project Symphony - Trademark Assignment Agreement [Executed]#page32.tif  
source=Project Symphony - Trademark Assignment Agreement [Executed]#page33.tif  
source=Project Symphony - Trademark Assignment Agreement [Executed]#page34.tif  
source=Project Symphony - Trademark Assignment Agreement [Executed]#page35.tif  
source=Project Symphony - Trademark Assignment Agreement [Executed]#page36.tif  
source=Project Symphony - Trademark Assignment Agreement [Executed]#page37.tif

source=Project Symphony - Trademark Assignment Agreement [Executed]#page38.tif  
source=Project Symphony - Trademark Assignment Agreement [Executed]#page39.tif  
source=Project Symphony - Trademark Assignment Agreement [Executed]#page40.tif  
source=Project Symphony - Trademark Assignment Agreement [Executed]#page41.tif  
source=Project Symphony - Trademark Assignment Agreement [Executed]#page42.tif  
source=Project Symphony - Trademark Assignment Agreement [Executed]#page43.tif  
source=Project Symphony - Trademark Assignment Agreement [Executed]#page44.tif  
source=Project Symphony - Trademark Assignment Agreement [Executed]#page45.tif  
source=Project Symphony - Trademark Assignment Agreement [Executed]#page46.tif  
source=Project Symphony - Trademark Assignment Agreement [Executed]#page47.tif  
source=Project Symphony - Trademark Assignment Agreement [Executed]#page48.tif  
source=Project Symphony - Trademark Assignment Agreement [Executed]#page49.tif  
source=Project Symphony - Trademark Assignment Agreement [Executed]#page50.tif  
source=Project Symphony - Trademark Assignment Agreement [Executed]#page51.tif  
source=Project Symphony - Trademark Assignment Agreement [Executed]#page52.tif  
source=Project Symphony - Trademark Assignment Agreement [Executed]#page53.tif  
source=Project Symphony - Trademark Assignment Agreement [Executed]#page54.tif  
source=Project Symphony - Trademark Assignment Agreement [Executed]#page55.tif  
source=Project Symphony - Trademark Assignment Agreement [Executed]#page56.tif

**PUBLIC DEED**

**Affidavit**

**BEFORE ME**, the undersigned Notary Public of the Canton Basel-City (Switzerland), Andrea Schmutz, have appeared today on the Novartis Campus, at Lichtstrasse 35, 4056 Basel, Switzerland:

- Ms **Isabelle Andrea Schubert Santana**, domiciled in Altstätten/SG, Canton of St. Gallen (Switzerland), born on 10<sup>th</sup> June 1965, identified by Swiss passport no. X0381156, with joint signature at two, and
- Mr **Robert Carroll Stanley**, american citizen, domiciled in Basel/BS, Canton of Basel-City (Switzerland), born on 15<sup>th</sup> November 1976, identified by american passport no. 548580188, with joint signature at two,

both acting not in their own name but for the Company **Novartis AG**, with registered office in Basel (Switzerland), and declared before me:

We confirm that we have been expressly informed by the undersigned Notary Public of Article 253 of the Swiss Penal Code, which reads literally:

*"Any person who by fraudulent means causes a public official or a person acting in an official capacity to certify an untrue fact of substantial legal significance, and in particular to certify a false signature or an incorrect copy as genuine, or any person who makes use of a document obtained by fraud in this way in order to deceive another as to the fact certified therein, shall be liable to a custodial sentence not exceeding five years or to a monetary penalty".*

After having been warned that therefore we must state the truth or be liable to the penalties prescribed by law if we fail to do so, we hereby declare as follows:

TRADEMARK ASSIGNMENT AGREEMENT

THIS TRADEMARK ASSIGNMENT AGREEMENT (this "Assignment"), dated as of September 29, 2023 (the "Effective Date"), is entered into by and between Novartis AG, a company incorporated in Switzerland ("Assignor"), and Bausch + Lomb Ireland Limited, a private company limited by shares under the laws of the Republic of Ireland ("Assignee"). Assignor and Assignee may be referred to herein individually as a "Party" and collectively as the "Parties."

Capitalized terms used but not defined in this Assignment shall have the respective meanings ascribed to them in that certain Stock and Asset Purchase Agreement, by and among Novartis Pharma AG, a company incorporated in Switzerland ("Swiss Seller"), Novartis Finance Corporation, a company incorporated in New York ("US Seller"), and Assignee, dated as of June 30, 2023 (the "Purchase Agreement").

WITNESSETH:

WHEREAS, pursuant to the terms and subject to the conditions of the Purchase Agreement, Swiss Seller and US Seller have agreed to cause Assignor to sell and assign to Assignee all of its rights, title and interest in, and Assignee has agreed to purchase and assume, among other things, the Purchased Trademarks (other than the transfer of Purchased Trademarks held by the Purchased Subsidiary, which shall be effected indirectly through the transfer of the Purchased Shares) (the Purchased Trademarks, other than those owned or held by the Purchased Subsidiary, are set forth on Schedule A and referred to herein as the "Assigned Trademarks"), each of which are owned by and registered to Novartis AG; and

WHEREAS, in connection with the transactions contemplated by the Purchase Agreement, Assignor desires to assign to Assignee, and Assignee desires to acquire from Assignor, all of Assignor's rights, title and interests in, to and under the Assigned Trademarks.

NOW, THEREFORE, for good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, and as more fully set forth in the Purchase Agreement, the Parties, intending to be legally bound, hereby agree as follows:

1. Assignor hereby sells, transfers, conveys, assigns and delivers to Assignee all of Assignor's rights, title and interests in, to and under, arising in any jurisdiction throughout the world: (i) the Assigned Trademarks, together with all goodwill associated therewith, in each case to be held and enjoyed by Assignee for its own use and enjoyment as fully and entirely as the same would have been held and enjoyed by the Assignor if this assignment and sale had not been made, (ii) any and all royalties, fees, income, payments and other proceeds now or hereafter due or payable with respect to any of the Assigned Trademarks, (iii) all rights to sue, claim and recover, including all rights to and claims for damages, restitution, and injunctive and other legal and equitable relief, for past, present and future infringement or other violation of any Assigned Trademarks, and to collect, or otherwise recover, any such damages, and (iv) all rights to claim priority, file foreign counterparts, and all other similar legal protections with respect to the Assigned Trademarks.

2. This Assignment is governed by the terms and conditions of the Purchase Agreement. The delivery of this Assignment shall not amend, affect, enlarge, diminish, supersede, modify, replace, rescind, waive or otherwise impair any of the representations, warranties, covenants, terms or provisions of the Purchase Agreement or any of the rights, remedies or obligations of US Seller, Swiss Seller or Assignee provided for therein or arising therefrom in any way, all of which shall remain in full force and effect in accordance with their terms. The representations, warranties, covenants, terms and provisions contained in the Purchase Agreement shall not be merged with or into this Assignment but shall survive the execution and delivery of this Assignment to the extent, and in the manner, set forth in the Purchase Agreement. In the event of any conflict or inconsistency between the terms of the Purchase Agreement and the terms of this Assignment, the terms of the Purchase Agreement shall control.
3. Promptly (and in any event within six months) following the Effective Date, subject to Assignor's prompt compliance with this Section 3, Assignee shall file this Assignment or such confirmatory assignment and other accompanying documents as may be required to record with the relevant trademark offices the assignment of each Assigned Trademark to Assignee. Upon Assignee's request, Assignor agrees to sign all necessary papers and do all lawful acts reasonably required to give effect to, and record the assignment of each Assigned Trademark to Assignee under, this Assignment, with Assignee bearing all out-of-pocket costs and expenses associated therewith, and with respect to any local forms that are required to record such assignment, Assignee shall consider in good faith reasonable comments of Assignor with respect to such local forms. Assignee hereby agrees to indemnify Assignor, US Seller, Swiss Seller and any of Assignor's Affiliates against all out-of-pocket Losses arising from any claim or proceeding brought against Assignor, US Seller, Swiss Seller or any of Assignor's Affiliates in connection with any Assigned Trademark (other than in connection with any use of any Assigned Trademark by or on behalf of Assignor, US Seller, Swiss Seller or any of its or their Affiliates) following the Effective Date for so long as Assignor or its Affiliate remains the registered owner of such Assigned Trademark unless Assignor or its Affiliate remains the registered owner due to its failure to promptly comply with this Section 3. Assignee shall control the defense or prosecution of such claim or proceeding in consultation with Assignor; provided that, prior to making any material filings or submissions or entering into any settlement or admission in connection with the defense or prosecution of any such claim or proceeding in the name of Assignor, US Seller, Swiss Seller or Assignor's Affiliates, Assignee must first consult with Assignor in good faith and obtain Assignor's written consent with respect thereto, such consent not to be unreasonably withheld, conditioned or delayed.
4. The Parties acknowledge and agree that any intent-to-use trademark applications assigned hereunder are being assigned by Assignor to Assignee as the successor to the business of Assignor, or portion thereof, to which the mark pertains, which business is ongoing and existing.
5. This Assignment will be governed by, and enforced and construed in accordance with, the Law of the State of Delaware, including its statute of limitations, without regard to the conflict of Laws rules of such state that would result in the application of the Laws of

another jurisdiction. This Assignment will be binding upon, inure to the benefit of, and be enforceable by, the Parties and their respective successors and permitted assigns. No waiver, modification or amendment of any provision of this Assignment shall be effective unless set forth in a written instrument executed by or on behalf of the Party against whom such claimed waiver, modification or amendment is sought to be enforced.

6. This Assignment may be executed in any number of counterparts and manually or electronically, and each such counterpart hereof shall be deemed to be an original, but all such counterparts together shall constitute but one agreement. Delivery of an executed counterpart of a signature page of this Assignment by electronic mail or other electronic transmission shall be effective as delivery of a manually executed original counterpart of this Assignment.

*[The remainder of this page has been intentionally left blank; Signature page follows.]*

IN WITNESS WHEREOF, the Parties have caused this Assignment to be duly executed by their respective authorized officers as of the Effective Date.

NOVARTIS AG

By: 

Name: *I. Schubot Santen*  
Title: *Authorized Signatory*

NOVARTIS AG

By: 

Name: **Robert Stanley**  
Title: **Authorized Signatory**

[Signature Page to Trademark Assignment Agreement]

**TRADEMARK**  
**REEL: 008235 FRAME: 0479**




BAUSCH + LOMB IRELAND LIMITED

By: Breda Furlong


Name: Breda Furlong

Title: Director

On this 29 day of Sept, 2023, before me personally, Breda Furlong, personally known to me (or proved to me on the basis of satisfactory evidence) to be the person whose name is subscribed to the within instrument and acknowledged to me that he or she executed the same in his or her authorized capacity, and that by his or her signature on the instrument the person, or the entity upon behalf of which the person acted, executed this instrument.

  
Notary Public

Colia Byrne  
Notary Public  
Dublin, Ireland  
Commissioned For Life



[Signature Page to Trademark Assignment Agreement]

**TRADEMARK**  
**REEL: 008235 FRAME: 0480**









ASSIGNED TRADEMARKS

*[See Attached]*

Schedule A

A-1



	<p>THE EYE SERVICE        17 May 2020 202012276        13 Aug 2020 202012276        National Drug        Registered        41        41. Trade mark services in the field of eye disease; providing medical information about eye disease. Healthcare AC (584)        and the treatment thereof.        15 Jul 2020</p>
	<p>THE EYE SERVICE        17 May 2020 202012276        13 Aug 2020 202012276        National Drug        Registered        41        41. Trade mark services in the field of eye disease; providing medical information about eye disease. Healthcare AC (584)        and the treatment thereof.        15 Jul 2020</p>
	<p>THE EYE SERVICE        17 May 2020 202012276        13 Aug 2020 202012276        National Drug        Registered        41        41. Trade mark services in the field of eye disease; providing medical information about eye disease. Healthcare AC (584)        and the treatment thereof.        15 Jul 2020</p>
	<p>THE EYE SERVICE        17 May 2020 202012276        13 Aug 2020 202012276        National Drug        Registered        41        41. Trade mark services in the field of eye disease; providing medical information about eye disease. Healthcare AC (584)        and the treatment thereof.        15 Jul 2020</p>
	<p>THE EYE SERVICE        17 May 2020 202012276        13 Aug 2020 202012276        National Drug        Registered        41        41. Trade mark services in the field of eye disease; providing medical information about eye disease. Healthcare AC (584)        and the treatment thereof.        15 Jul 2020</p>
	<p>THE EYE SERVICE        17 May 2020 202012276        13 Aug 2020 202012276        National Drug        Registered        41        41. Trade mark services in the field of eye disease; providing medical information about eye disease. Healthcare AC (584)        and the treatment thereof.        15 Jul 2020</p>
	<p>THE EYE SERVICE        17 May 2020 202012276        13 Aug 2020 202012276        National Drug        Registered        41        41. Trade mark services in the field of eye disease; providing medical information about eye disease. Healthcare AC (584)        and the treatment thereof.        15 Jul 2020</p>
	<p>THE EYE SERVICE        17 May 2020 202012276        13 Aug 2020 202012276        National Drug        Registered        41        41. Trade mark services in the field of eye disease; providing medical information about eye disease. Healthcare AC (584)        and the treatment thereof.        15 Jul 2020</p>




















Page	Line	Text	Page	Line	Text
1	1	1	1	1	1
1	2	2	1	2	2
1	3	3	1	3	3
1	4	4	1	4	4
1	5	5	1	5	5
1	6	6	1	6	6
1	7	7	1	7	7
1	8	8	1	8	8
1	9	9	1	9	9
1	10	10	1	10	10
1	11	11	1	11	11
1	12	12	1	12	12
1	13	13	1	13	13
1	14	14	1	14	14
1	15	15	1	15	15
1	16	16	1	16	16
1	17	17	1	17	17
1	18	18	1	18	18
1	19	19	1	19	19
1	20	20	1	20	20
1	21	21	1	21	21
1	22	22	1	22	22
1	23	23	1	23	23
1	24	24	1	24	24
1	25	25	1	25	25
1	26	26	1	26	26
1	27	27	1	27	27
1	28	28	1	28	28
1	29	29	1	29	29
1	30	30	1	30	30
1	31	31	1	31	31
1	32	32	1	32	32
1	33	33	1	33	33
1	34	34	1	34	34
1	35	35	1	35	35
1	36	36	1	36	36
1	37	37	1	37	37
1	38	38	1	38	38
1	39	39	1	39	39
1	40	40	1	40	40
1	41	41	1	41	41
1	42	42	1	42	42
1	43	43	1	43	43
1	44	44	1	44	44
1	45	45	1	45	45
1	46	46	1	46	46
1	47	47	1	47	47
1	48	48	1	48	48
1	49	49	1	49	49
1	50	50	1	50	50
1	51	51	1	51	51
1	52	52	1	52	52
1	53	53	1	53	53
1	54	54	1	54	54
1	55	55	1	55	55
1	56	56	1	56	56
1	57	57	1	57	57
1	58	58	1	58	58
1	59	59	1	59	59
1	60	60	1	60	60
1	61	61	1	61	61
1	62	62	1	62	62
1	63	63	1	63	63
1	64	64	1	64	64
1	65	65	1	65	65
1	66	66	1	66	66
1	67	67	1	67	67
1	68	68	1	68	68
1	69	69	1	69	69
1	70	70	1	70	70
1	71	71	1	71	71
1	72	72	1	72	72
1	73	73	1	73	73
1	74	74	1	74	74
1	75	75	1	75	75
1	76	76	1	76	76
1	77	77	1	77	77
1	78	78	1	78	78
1	79	79	1	79	79
1	80	80	1	80	80
1	81	81	1	81	81
1	82	82	1	82	82
1	83	83	1	83	83
1	84	84	1	84	84
1	85	85	1	85	85
1	86	86	1	86	86
1	87	87	1	87	87
1	88	88	1	88	88
1	89	89	1	89	89
1	90	90	1	90	90
1	91	91	1	91	91
1	92	92	1	92	92
1	93	93	1	93	93
1	94	94	1	94	94
1	95	95	1	95	95
1	96	96	1	96	96
1	97	97	1	97	97
1	98	98	1	98	98
1	99	99	1	99	99
1	100	100	1	100	100









	1. (b) (6), (b) (7)(C), (b) (7)(D)	17 Aug 2022 19:00:00	23 Sep 2021 19:12:22	National Being	Pending	24	<p>42. "Health" has no relation to the field of eye disease, providing medical information about eye disease, identifying eye disease, and the treatment thereof.</p>	15/08/2022
	1. (b) (6), (b) (7)(C), (b) (7)(D)	20 Sep 2022 19:00:00	23 Sep 2021 19:12:22	National Being	Pending	24	<p>42. "Health" has no relation to the field of eye disease, providing medical information about eye disease, identifying eye disease, and the treatment thereof.</p>	15/08/2022
	1. (b) (6), (b) (7)(C), (b) (7)(D)	27 Aug 2022 19:00:00	23 Sep 2021 19:12:22	National Being	Pending	24	<p>42. "Health" has no relation to the field of eye disease, providing medical information about eye disease, identifying eye disease, and the treatment thereof.</p>	15/08/2022
	1. (b) (6), (b) (7)(C), (b) (7)(D)	16 Sep 2022 19:00:00	23 Sep 2021 19:12:22	National Being	Pending	24	<p>42. "Health" has no relation to the field of eye disease, providing medical information about eye disease, identifying eye disease, and the treatment thereof.</p>	15/08/2022
	1. (b) (6), (b) (7)(C), (b) (7)(D)	23 Aug 2022 19:00:00	23 Sep 2021 19:12:22	National Being	Pending	24	<p>42. "Health" has no relation to the field of eye disease, providing medical information about eye disease, identifying eye disease, and the treatment thereof.</p>	15/08/2022
	1. (b) (6), (b) (7)(C), (b) (7)(D)	05 Sep 2022 19:00:00	23 Sep 2021 19:12:22	National Being	Pending	24	<p>42. "Health" has no relation to the field of eye disease, providing medical information about eye disease, identifying eye disease, and the treatment thereof.</p>	15/08/2022
	1. (b) (6), (b) (7)(C), (b) (7)(D)	27 Aug 2022 19:00:00	23 Sep 2021 19:12:22	National Being	Pending	24	<p>42. "Health" has no relation to the field of eye disease, providing medical information about eye disease, identifying eye disease, and the treatment thereof.</p>	15/08/2022
	1. (b) (6), (b) (7)(C), (b) (7)(D)	08 Sep 2022 19:00:00	23 Sep 2021 19:12:22	National Being	Pending	24	<p>42. "Health" has no relation to the field of eye disease, providing medical information about eye disease, identifying eye disease, and the treatment thereof.</p>	15/08/2022
	1. (b) (6), (b) (7)(C), (b) (7)(D)	08 Sep 2022 19:00:00	23 Sep 2021 19:12:22	National Being	Pending	24	<p>42. "Health" has no relation to the field of eye disease, providing medical information about eye disease, identifying eye disease, and the treatment thereof.</p>	15/08/2022

Printed Name: [illegible]

Printed Name: [illegible]

Printed Name: [illegible]

Printed Name: [illegible]

Printed Name: [illegible]

Printed Name: [illegible]

Printed Name: [illegible]

Printed Name: [illegible]

Printed Name: [illegible]

Printed Name: [illegible]



Printed Name: [illegible]

Printed Name: [illegible]

Printed Name: [illegible]

Printed Name: [illegible]

Printed Name: [illegible]

Pharmaceutical preparation for the treatment of dry eye disease...

Pharmaceutical preparation...

[illegible]

Pharmaceutical preparation...

[illegible]

Pharmaceutical preparation for the treatment of dry eye disease...

[illegible]

Pharmaceutical preparation...

[illegible]





2018099952626  
ZODARI  
25001 Kashiha  
19 MAY 2015 201534844  
National Drug  
Product  
05  
Pharmaceutical preparations  
NANDA 02 (139)

2018099952627  
ZODARI  
Kashira  
23 MAY 2015 201534844  
National Drug  
Product  
05  
Pharmaceutical preparations  
NANDA 02 (139)

2018099952628  
ZODARI  
Kashira  
23 MAY 2015 201534844  
National Drug  
Product  
05  
Pharmaceutical preparations  
NANDA 02 (139)

2018099952629  
ZODARI  
Kashira  
23 MAY 2015 201534844  
National Drug  
Product  
05  
Pharmaceutical preparations  
NANDA 02 (139)

2018099952630  
ZODARI  
Kashira  
23 MAY 2015 201534844  
National Drug  
Product  
05  
Pharmaceutical preparations  
NANDA 02 (139)

2018099952631  
ZODARI  
Kashira  
23 MAY 2015 201534844  
National Drug  
Product  
05  
Pharmaceutical preparations  
NANDA 02 (139)

2018099952632  
ZODARI  
Kashira  
23 MAY 2015 201534844  
National Drug  
Product  
05  
Pharmaceutical preparations  
NANDA 02 (139)

2018099952633  
ZODARI  
Kashira  
23 MAY 2015 201534844  
National Drug  
Product  
05  
Pharmaceutical preparations  
NANDA 02 (139)

2018099952634  
ZODARI  
Kashira  
23 MAY 2015 201534844  
National Drug  
Product  
05  
Pharmaceutical preparations  
NANDA 02 (139)

2018099952635  
ZODARI  
Kashira  
23 MAY 2015 201534844  
National Drug  
Product  
05  
Pharmaceutical preparations  
NANDA 02 (139)

Applicant	Product Name	Application No.	Date of Filing	Priority Date	Class	Registration Status	Remarks	Effective Date
Novartis AG	Novartis	15 Nov 2016 1328617	15 Nov 2016 1328617	15 Nov 2016 1328617	Pharmaceutical preparations	Registered	Novartis AG (25)	15 Nov 2016
Novartis AG	Novartis	16 Nov 2016 1328617	16 Nov 2016 1328617	16 Nov 2016 1328617	Pharmaceutical preparations	Registered	Novartis AG (25)	16 Nov 2016
Novartis AG	Novartis	17 Nov 2016 1328617	17 Nov 2016 1328617	17 Nov 2016 1328617	Pharmaceutical preparations	Registered	Novartis AG (25)	17 Nov 2016
Novartis AG	Novartis	18 Nov 2016 1328617	18 Nov 2016 1328617	18 Nov 2016 1328617	Pharmaceutical preparations	Registered	Novartis AG (25)	18 Nov 2016
Novartis AG	Novartis	19 Nov 2016 1328617	19 Nov 2016 1328617	19 Nov 2016 1328617	Pharmaceutical preparations	Registered	Novartis AG (25)	19 Nov 2016
Novartis AG	Novartis	20 Nov 2016 1328617	20 Nov 2016 1328617	20 Nov 2016 1328617	Pharmaceutical preparations	Registered	Novartis AG (25)	20 Nov 2016
Novartis AG	Novartis	21 Nov 2016 1328617	21 Nov 2016 1328617	21 Nov 2016 1328617	Pharmaceutical preparations	Registered	Novartis AG (25)	21 Nov 2016
Novartis AG	Novartis	22 Nov 2016 1328617	22 Nov 2016 1328617	22 Nov 2016 1328617	Pharmaceutical preparations	Registered	Novartis AG (25)	22 Nov 2016
Novartis AG	Novartis	23 Nov 2016 1328617	23 Nov 2016 1328617	23 Nov 2016 1328617	Pharmaceutical preparations	Registered	Novartis AG (25)	23 Nov 2016
Novartis AG	Novartis	24 Nov 2016 1328617	24 Nov 2016 1328617	24 Nov 2016 1328617	Pharmaceutical preparations	Registered	Novartis AG (25)	24 Nov 2016
Novartis AG	Novartis	25 Nov 2016 1328617	25 Nov 2016 1328617	25 Nov 2016 1328617	Pharmaceutical preparations	Registered	Novartis AG (25)	25 Nov 2016
Novartis AG	Novartis	26 Nov 2016 1328617	26 Nov 2016 1328617	26 Nov 2016 1328617	Pharmaceutical preparations	Registered	Novartis AG (25)	26 Nov 2016
Novartis AG	Novartis	27 Nov 2016 1328617	27 Nov 2016 1328617	27 Nov 2016 1328617	Pharmaceutical preparations	Registered	Novartis AG (25)	27 Nov 2016
Novartis AG	Novartis	28 Nov 2016 1328617	28 Nov 2016 1328617	28 Nov 2016 1328617	Pharmaceutical preparations	Registered	Novartis AG (25)	28 Nov 2016
Novartis AG	Novartis	29 Nov 2016 1328617	29 Nov 2016 1328617	29 Nov 2016 1328617	Pharmaceutical preparations	Registered	Novartis AG (25)	29 Nov 2016
Novartis AG	Novartis	30 Nov 2016 1328617	30 Nov 2016 1328617	30 Nov 2016 1328617	Pharmaceutical preparations	Registered	Novartis AG (25)	30 Nov 2016
Novartis AG	Novartis	31 Nov 2016 1328617	31 Nov 2016 1328617	31 Nov 2016 1328617	Pharmaceutical preparations	Registered	Novartis AG (25)	31 Nov 2016

202001-00101117 11 Nov 2020 01:58:01 1735 15 Nov 2020  
15 Nov 2020

202001-00101117 16 Nov 2020 08:02:11 1735 15 Nov 2020  
15 Nov 2020

202001-00101117 23 Oct 2020 22:01:52 1735 15 Nov 2020  
15 Nov 2020

202001-00101117 23 Oct 2020 22:01:52 1735 15 Nov 2020  
15 Nov 2020

202001-00101117 15 Oct 2020 20:01:52 1735 15 Nov 2020  
15 Nov 2020

202001-00101117 22 Nov 2020 01:58:01 1735 15 Nov 2020  
15 Nov 2020

202001-00101117 07 Nov 2020 01:58:01 1735 15 Nov 2020  
15 Nov 2020

202001-00101117 27 Sep 2020 15:30:57 1735 15 Nov 2020  
15 Nov 2020

202001-00101117 06 Nov 2020 15:30:57 1735 15 Nov 2020  
15 Nov 2020

202001-00101117 12 Nov 2020 08:02:11 1735 15 Nov 2020  
15 Nov 2020

12/15/2017 10:00:00 AM 12/15/2017 10:00:00 AM 12/15/2017 10:00:00 AM 12/15/2017 10:00:00 AM

12/15/2017 10:00:00 AM 12/15/2017 10:00:00 AM 12/15/2017 10:00:00 AM 12/15/2017 10:00:00 AM

12/15/2017 10:00:00 AM 12/15/2017 10:00:00 AM 12/15/2017 10:00:00 AM 12/15/2017 10:00:00 AM

12/15/2017 10:00:00 AM 12/15/2017 10:00:00 AM 12/15/2017 10:00:00 AM 12/15/2017 10:00:00 AM

12/15/2017 10:00:00 AM 12/15/2017 10:00:00 AM 12/15/2017 10:00:00 AM 12/15/2017 10:00:00 AM

12/15/2017 10:00:00 AM 12/15/2017 10:00:00 AM 12/15/2017 10:00:00 AM 12/15/2017 10:00:00 AM

12/15/2017 10:00:00 AM 12/15/2017 10:00:00 AM 12/15/2017 10:00:00 AM 12/15/2017 10:00:00 AM

12/15/2017 10:00:00 AM 12/15/2017 10:00:00 AM 12/15/2017 10:00:00 AM 12/15/2017 10:00:00 AM

12/15/2017 10:00:00 AM 12/15/2017 10:00:00 AM 12/15/2017 10:00:00 AM 12/15/2017 10:00:00 AM

12/15/2017 10:00:00 AM 12/15/2017 10:00:00 AM 12/15/2017 10:00:00 AM 12/15/2017 10:00:00 AM

12/15/2017 10:00:00 AM 12/15/2017 10:00:00 AM 12/15/2017 10:00:00 AM 12/15/2017 10:00:00 AM

12/15/2017 10:00:00 AM 12/15/2017 10:00:00 AM 12/15/2017 10:00:00 AM 12/15/2017 10:00:00 AM

ALPHABET	ALPHABET	ALPHABET	ALPHABET	ALPHABET	ALPHABET	ALPHABET	ALPHABET	ALPHABET	ALPHABET
01	02	03	04	05	06	07	08	09	10
11	12	13	14	15	16	17	18	19	20
21	22	23	24	25	26	27	28	29	30
31	32	33	34	35	36	37	38	39	40
41	42	43	44	45	46	47	48	49	50
51	52	53	54	55	56	57	58	59	60
61	62	63	64	65	66	67	68	69	70
71	72	73	74	75	76	77	78	79	80
81	82	83	84	85	86	87	88	89	90
91	92	93	94	95	96	97	98	99	00

Patent No.	Inventor	Date	Class	Title	Abstract	Pub. No.	Pub. Date
2,819,823	James W. Smith	11 Feb 1958	281	Pharmaceutical preparation for the treatment of eye eye infections	...	2,819,823	11 Feb 1958
2,819,824	James W. Smith	11 Feb 1958	281	Pharmaceutical preparation for the treatment of eye eye infections	...	2,819,824	11 Feb 1958
2,819,825	James W. Smith	11 Feb 1958	281	Pharmaceutical preparation for the treatment of eye eye infections	...	2,819,825	11 Feb 1958
2,819,826	James W. Smith	11 Feb 1958	281	Pharmaceutical preparation for the treatment of eye eye infections	...	2,819,826	11 Feb 1958
2,819,827	James W. Smith	11 Feb 1958	281	Pharmaceutical preparation for the treatment of eye eye infections	...	2,819,827	11 Feb 1958
2,819,828	James W. Smith	11 Feb 1958	281	Pharmaceutical preparation for the treatment of eye eye infections	...	2,819,828	11 Feb 1958
2,819,829	James W. Smith	11 Feb 1958	281	Pharmaceutical preparation for the treatment of eye eye infections	...	2,819,829	11 Feb 1958
2,819,830	James W. Smith	11 Feb 1958	281	Pharmaceutical preparation for the treatment of eye eye infections	...	2,819,830	11 Feb 1958
2,819,831	James W. Smith	11 Feb 1958	281	Pharmaceutical preparation for the treatment of eye eye infections	...	2,819,831	11 Feb 1958
2,819,832	James W. Smith	11 Feb 1958	281	Pharmaceutical preparation for the treatment of eye eye infections	...	2,819,832	11 Feb 1958
2,819,833	James W. Smith	11 Feb 1958	281	Pharmaceutical preparation for the treatment of eye eye infections	...	2,819,833	11 Feb 1958
2,819,834	James W. Smith	11 Feb 1958	281	Pharmaceutical preparation for the treatment of eye eye infections	...	2,819,834	11 Feb 1958
2,819,835	James W. Smith	11 Feb 1958	281	Pharmaceutical preparation for the treatment of eye eye infections	...	2,819,835	11 Feb 1958
2,819,836	James W. Smith	11 Feb 1958	281	Pharmaceutical preparation for the treatment of eye eye infections	...	2,819,836	11 Feb 1958
2,819,837	James W. Smith	11 Feb 1958	281	Pharmaceutical preparation for the treatment of eye eye infections	...	2,819,837	11 Feb 1958
2,819,838	James W. Smith	11 Feb 1958	281	Pharmaceutical preparation for the treatment of eye eye infections	...	2,819,838	11 Feb 1958
2,819,839	James W. Smith	11 Feb 1958	281	Pharmaceutical preparation for the treatment of eye eye infections	...	2,819,839	11 Feb 1958
2,819,840	James W. Smith	11 Feb 1958	281	Pharmaceutical preparation for the treatment of eye eye infections	...	2,819,840	11 Feb 1958



South Korea  
Republic of Korea  
28 Jun 2007 144514  
28 Jun 2007 144514  
Hull of Patent  
Kapsulca  
01  
02  
03  
04  
05  
06  
07  
08  
09  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65  
66  
67  
68  
69  
70  
71  
72  
73  
74  
75  
76  
77  
78  
79  
80  
81  
82  
83  
84  
85  
86  
87  
88  
89  
90  
91  
92  
93  
94  
95  
96  
97  
98  
99  
100  
101  
102  
103  
104  
105  
106  
107  
108  
109  
110  
111  
112  
113  
114  
115  
116  
117  
118  
119  
120  
121  
122  
123  
124  
125  
126  
127  
128  
129  
130  
131  
132  
133  
134  
135  
136  
137  
138  
139  
140  
141  
142  
143  
144  
145  
146  
147  
148  
149  
150  
151  
152  
153  
154  
155  
156  
157  
158  
159  
160  
161  
162  
163  
164  
165  
166  
167  
168  
169  
170  
171  
172  
173  
174  
175  
176  
177  
178  
179  
180  
181  
182  
183  
184  
185  
186  
187  
188  
189  
190  
191  
192  
193  
194  
195  
196  
197  
198  
199  
200  
201  
202  
203  
204  
205  
206  
207  
208  
209  
210  
211  
212  
213  
214  
215  
216  
217  
218  
219  
220  
221  
222  
223  
224  
225  
226  
227  
228  
229  
230  
231  
232  
233  
234  
235  
236  
237  
238  
239  
240  
241  
242  
243  
244  
245  
246  
247  
248  
249  
250  
251  
252  
253  
254  
255  
256  
257  
258  
259  
260  
261  
262  
263  
264  
265  
266  
267  
268  
269  
270  
271  
272  
273  
274  
275  
276  
277  
278  
279  
280  
281  
282  
283  
284  
285  
286  
287  
288  
289  
290  
291  
292  
293  
294  
295  
296  
297  
298  
299  
300  
301  
302  
303  
304  
305  
306  
307  
308  
309  
310  
311  
312  
313  
314  
315  
316  
317  
318  
319  
320  
321  
322  
323  
324  
325  
326  
327  
328  
329  
330  
331  
332  
333  
334  
335  
336  
337  
338  
339  
340  
341  
342  
343  
344  
345  
346  
347  
348  
349  
350  
351  
352  
353  
354  
355  
356  
357  
358  
359  
360  
361  
362  
363  
364  
365  
366  
367  
368  
369  
370  
371  
372  
373  
374  
375  
376  
377  
378  
379  
380  
381  
382  
383  
384  
385  
386  
387  
388  
389  
390  
391  
392  
393  
394  
395  
396  
397  
398  
399  
400  
401  
402  
403  
404  
405  
406  
407  
408  
409  
410  
411  
412  
413  
414  
415  
416  
417  
418  
419  
420  
421  
422  
423  
424  
425  
426  
427  
428  
429  
430  
431  
432  
433  
434  
435  
436  
437  
438  
439  
440  
441  
442  
443  
444  
445  
446  
447  
448  
449  
450  
451  
452  
453  
454  
455  
456  
457  
458  
459  
460  
461  
462  
463  
464  
465  
466  
467  
468  
469  
470  
471  
472  
473  
474  
475  
476  
477  
478  
479  
480  
481  
482  
483  
484  
485  
486  
487  
488  
489  
490  
491  
492  
493  
494  
495  
496  
497  
498  
499  
500  
501  
502  
503  
504  
505  
506  
507  
508  
509  
510  
511  
512  
513  
514  
515  
516  
517  
518  
519  
520  
521  
522  
523  
524  
525  
526  
527  
528  
529  
530  
531  
532  
533  
534  
535  
536  
537  
538  
539  
540  
541  
542  
543  
544  
545  
546  
547  
548  
549  
550  
551  
552  
553  
554  
555  
556  
557  
558  
559  
560  
561  
562  
563  
564  
565  
566  
567  
568  
569  
570  
571  
572  
573  
574  
575  
576  
577  
578  
579  
580  
581  
582  
583  
584  
585  
586  
587  
588  
589  
590  
591  
592  
593  
594  
595  
596  
597  
598  
599  
600  
601  
602  
603  
604  
605  
606  
607  
608  
609  
610  
611  
612  
613  
614  
615  
616  
617  
618  
619  
620  
621  
622  
623  
624  
625  
626  
627  
628  
629  
630  
631  
632  
633  
634  
635  
636  
637  
638  
639  
640  
641  
642  
643  
644  
645  
646  
647  
648  
649  
650  
651  
652  
653  
654  
655  
656  
657  
658  
659  
660  
661  
662  
663  
664  
665  
666  
667  
668  
669  
670  
671  
672  
673  
674  
675  
676  
677  
678  
679  
680  
681  
682  
683  
684  
685  
686  
687  
688  
689  
690  
691  
692  
693  
694  
695  
696  
697  
698  
699  
700  
701  
702  
703  
704  
705  
706  
707  
708  
709  
710  
711  
712  
713  
714  
715  
716  
717  
718  
719  
720  
721  
722  
723  
724  
725  
726  
727  
728  
729  
730  
731  
732  
733  
734  
735  
736  
737  
738  
739  
740  
741  
742  
743  
744  
745  
746  
747  
748  
749  
750  
751  
752  
753  
754  
755  
756  
757  
758  
759  
760  
761  
762  
763  
764  
765  
766  
767  
768  
769  
770  
771  
772  
773  
774  
775  
776  
777  
778  
779  
780  
781  
782  
783  
784  
785  
786  
787  
788  
789  
790  
791  
792  
793  
794  
795  
796  
797  
798  
799  
800  
801  
802  
803  
804  
805  
806  
807  
808  
809  
810  
811  
812  
813  
814  
815  
816  
817  
818  
819  
820  
821  
822  
823  
824  
825  
826  
827  
828  
829  
830  
831  
832  
833  
834  
835  
836  
837  
838  
839  
840  
841  
842  
843  
844  
845  
846  
847  
848  
849  
850  
851  
852  
853  
854  
855  
856  
857  
858  
859  
860  
861  
862  
863  
864  
865  
866  
867  
868  
869  
870  
871  
872  
873  
874  
875  
876  
877  
878  
879  
880  
881  
882  
883  
884  
885  
886  
887  
888  
889  
890  
891  
892  
893  
894  
895  
896  
897  
898  
899  
900  
901  
902  
903  
904  
905  
906  
907  
908  
909  
910  
911  
912  
913  
914  
915  
916  
917  
918  
919  
920  
921  
922  
923  
924  
925  
926  
927  
928  
929  
930  
931  
932  
933  
934  
935  
936  
937  
938  
939  
940  
941  
942  
943  
944  
945  
946  
947  
948  
949  
950  
951  
952  
953  
954  
955  
956  
957  
958  
959  
960  
961  
962  
963  
964  
965  
966  
967  
968  
969  
970  
971  
972  
973  
974  
975  
976  
977  
978  
979  
980  
981  
982  
983  
984  
985  
986  
987  
988  
989  
990  
991  
992  
993  
994  
995  
996  
997  
998  
999  
1000



18 Jan 2017 15:51:31

42 Jan 2017 14:07:13

11 Jan 2017 14:07:13

01 Jan 2017 14:07:13

18 Jan 2017

26 Jan 2017

XIN004 Pusan Petroleum

17 Feb 2015 10:30:04

12 Nov 2015 15:39:02

National filing

Registered

03

05: The above pharmaceutical preparation for the treatment of an eye disease

Novartis AG (834)

27 Feb 2016

XIN004 Quat

23 Nov 2015 13:49:55

03 Jan 2016 13:58:53

National filing

Registered

03

05: Miconazole preparations

Novartis AG (834)

27 Feb 2016

XIN004 Quat

23 Nov 2015 13:49:55

03 Jan 2016 13:58:53

National filing

Registered

03

05: The above pharmaceutical preparation for the treatment of an eye disease

Novartis AG (834)

27 Feb 2016

XIN004 Quat

23 Nov 2015 13:49:55

03 Jan 2016 13:58:53

National filing

Registered

03

05: The above pharmaceutical preparation

Novartis AG (834)

27 Feb 2016

XIN004 Quat

23 Nov 2015 13:49:55

11 Nov 2016 01:17:57

National filing

Registered

03

05: The above pharmaceutical preparation

Novartis AG (834)

23 Nov 2016

XIN004 Quat

23 Nov 2015 13:49:55

10 Dec 2015 23:53:53

National filing

Registered

03

05: The above pharmaceutical preparation

Novartis AG (834)

23 Nov 2016

XIN004 Quat

23 Nov 2015 13:49:55

08 Nov 2015 09:59:57

National filing

Registered

03

05: The above pharmaceutical preparation

Novartis AG (834)

23 Nov 2016

05: The above pharmaceutical preparation for the treatment of an eye disease

Patent No.	Inventor	Date of Patent	Class	Priority	Abstract	Pub. No.	Pub. Date
2,812,000	W. H. R. R. R.	1958	21	2,812,000	Pharmaceutical preparations for the treatment of dry eye syndrome.	2,812,000	1958
2,812,001	W. H. R. R. R.	1958	21	2,812,001	Pharmaceutical preparations for the treatment of dry eye syndrome.	2,812,001	1958
2,812,002	W. H. R. R. R.	1958	21	2,812,002	Pharmaceutical preparations for the treatment of dry eye syndrome.	2,812,002	1958
2,812,003	W. H. R. R. R.	1958	21	2,812,003	Pharmaceutical preparations for the treatment of dry eye syndrome.	2,812,003	1958
2,812,004	W. H. R. R. R.	1958	21	2,812,004	Pharmaceutical preparations for the treatment of dry eye syndrome.	2,812,004	1958
2,812,005	W. H. R. R. R.	1958	21	2,812,005	Pharmaceutical preparations for the treatment of dry eye syndrome.	2,812,005	1958
2,812,006	W. H. R. R. R.	1958	21	2,812,006	Pharmaceutical preparations for the treatment of dry eye syndrome.	2,812,006	1958
2,812,007	W. H. R. R. R.	1958	21	2,812,007	Pharmaceutical preparations for the treatment of dry eye syndrome.	2,812,007	1958
2,812,008	W. H. R. R. R.	1958	21	2,812,008	Pharmaceutical preparations for the treatment of dry eye syndrome.	2,812,008	1958
2,812,009	W. H. R. R. R.	1958	21	2,812,009	Pharmaceutical preparations for the treatment of dry eye syndrome.	2,812,009	1958
2,812,010	W. H. R. R. R.	1958	21	2,812,010	Pharmaceutical preparations for the treatment of dry eye syndrome.	2,812,010	1958

NO.	CLASS	MARK	FILED	EXPIRES	STATUS	REMARKS	REGISTRATION NO.	ISSUE DATE
1	35	Merchandise	01 Dec 2019	13 Dec 2024	Registered	Merchandise	01	15 Nov 2020
2	35	Merchandise	26 Jun 2020	14 Jun 2025	Registered	Merchandise	02	26 Jun 2020
3	35	Merchandise	26 Jun 2020	14 Jun 2025	Registered	Merchandise	03	26 Jun 2020
4	35	Merchandise	26 Jun 2020	14 Jun 2025	Registered	Merchandise	04	26 Jun 2020
5	35	Merchandise	26 Jun 2020	14 Jun 2025	Registered	Merchandise	05	26 Jun 2020
6	35	Merchandise	26 Jun 2020	14 Jun 2025	Registered	Merchandise	06	26 Jun 2020
7	35	Merchandise	26 Jun 2020	14 Jun 2025	Registered	Merchandise	07	26 Jun 2020
8	35	Merchandise	26 Jun 2020	14 Jun 2025	Registered	Merchandise	08	26 Jun 2020
9	35	Merchandise	26 Jun 2020	14 Jun 2025	Registered	Merchandise	09	26 Jun 2020
10	35	Merchandise	26 Jun 2020	14 Jun 2025	Registered	Merchandise	10	26 Jun 2020
11	35	Merchandise	26 Jun 2020	14 Jun 2025	Registered	Merchandise	11	26 Jun 2020
12	35	Merchandise	26 Jun 2020	14 Jun 2025	Registered	Merchandise	12	26 Jun 2020
13	35	Merchandise	26 Jun 2020	14 Jun 2025	Registered	Merchandise	13	26 Jun 2020
14	35	Merchandise	26 Jun 2020	14 Jun 2025	Registered	Merchandise	14	26 Jun 2020
15	35	Merchandise	26 Jun 2020	14 Jun 2025	Registered	Merchandise	15	26 Jun 2020
16	35	Merchandise	26 Jun 2020	14 Jun 2025	Registered	Merchandise	16	26 Jun 2020
17	35	Merchandise	26 Jun 2020	14 Jun 2025	Registered	Merchandise	17	26 Jun 2020
18	35	Merchandise	26 Jun 2020	14 Jun 2025	Registered	Merchandise	18	26 Jun 2020
19	35	Merchandise	26 Jun 2020	14 Jun 2025	Registered	Merchandise	19	26 Jun 2020
20	35	Merchandise	26 Jun 2020	14 Jun 2025	Registered	Merchandise	20	26 Jun 2020



23 Jun 2026 15:00:14 25 Jun 2026 15:00:14 Registered Registered 05 05 17 May 2026

30 Jun 2026 15:00:14 31 Jun 2026 15:00:14 Registered Registered 05 05 26 Jun 2026

17 May 2026 17:30:05 22 Jun 2026 17:30:05 Registered Registered 05 05 17 May 2026

02 May 2015 19:00:00 02 May 2015 19:00:00 Registered Registered 05 05 16 Sep 2026

23 Jun 2026 15:00:14 24 Jun 2026 15:00:14 Registered Registered 05 05 23 Jun 2026

23 Jun 2026 15:00:14 24 Jun 2026 15:00:14 Registered Registered 05 05 23 Jun 2026

12 May 2017 13:00:31 12 May 2017 13:00:31 Registered Registered 05 05 12 May 2017

057: Pharmaceutical preparations for the prevention and treatment of eye infections.

057: Pharmaceutical preparations for the prevention and treatment of eye infections.

057: Multi-dose, anti-inflammatory, ophthalmic pharmaceutical products, including pharmaceutical preparations for the prevention and treatment of eye infections.

Patent No.	Inventor	Date	Class	Priority	Applicant	Attorney	Agent	Notes
3,820,000	W. H. ...	1974	...	...	...	...	...	...
3,820,001	W. H. ...	1974	...	...	...	...	...	...
3,820,002	W. H. ...	1974	...	...	...	...	...	...
3,820,003	W. H. ...	1974	...	...	...	...	...	...
3,820,004	W. H. ...	1974	...	...	...	...	...	...
3,820,005	W. H. ...	1974	...	...	...	...	...	...
3,820,006	W. H. ...	1974	...	...	...	...	...	...
3,820,007	W. H. ...	1974	...	...	...	...	...	...
3,820,008	W. H. ...	1974	...	...	...	...	...	...
3,820,009	W. H. ...	1974	...	...	...	...	...	...
3,820,010	W. H. ...	1974	...	...	...	...	...	...
3,820,011	W. H. ...	1974	...	...	...	...	...	...
3,820,012	W. H. ...	1974	...	...	...	...	...	...
3,820,013	W. H. ...	1974	...	...	...	...	...	...
3,820,014	W. H. ...	1974	...	...	...	...	...	...
3,820,015	W. H. ...	1974	...	...	...	...	...	...
3,820,016	W. H. ...	1974	...	...	...	...	...	...
3,820,017	W. H. ...	1974	...	...	...	...	...	...
3,820,018	W. H. ...	1974	...	...	...	...	...	...
3,820,019	W. H. ...	1974	...	...	...	...	...	...
3,820,020	W. H. ...	1974	...	...	...	...	...	...
3,820,021	W. H. ...	1974	...	...	...	...	...	...
3,820,022	W. H. ...	1974	...	...	...	...	...	...
3,820,023	W. H. ...	1974	...	...	...	...	...	...
3,820,024	W. H. ...	1974	...	...	...	...	...	...
3,820,025	W. H. ...	1974	...	...	...	...	...	...
3,820,026	W. H. ...	1974	...	...	...	...	...	...
3,820,027	W. H. ...	1974	...	...	...	...	...	...
3,820,028	W. H. ...	1974	...	...	...	...	...	...
3,820,029	W. H. ...	1974	...	...	...	...	...	...
3,820,030	W. H. ...	1974	...	...	...	...	...	...










Application No.	Applicant	Priority Date	International Class	Goods/Services Description	Attorney	Filing Date	Status
2002080139	WANTON PHARMACEUTICALS, INC.	28 Jul 2001	5	Pharmaceutical preparations; medicaments.	WANTON PHARMACEUTICALS, INC.	28 Jul 2001	Pending
2002080140	WANTON PHARMACEUTICALS, INC.	28 Jul 2001	5	Pharmaceutical preparations; medicaments.	WANTON PHARMACEUTICALS, INC.	28 Jul 2001	Pending
2002080141	WANTON PHARMACEUTICALS, INC.	28 Jul 2001	5	Pharmaceutical preparations; medicaments.	WANTON PHARMACEUTICALS, INC.	28 Jul 2001	Pending
2002080142	WANTON PHARMACEUTICALS, INC.	28 Jul 2001	5	Pharmaceutical preparations; medicaments.	WANTON PHARMACEUTICALS, INC.	28 Jul 2001	Pending
2002080143	WANTON PHARMACEUTICALS, INC.	28 Jul 2001	5	Pharmaceutical preparations; medicaments.	WANTON PHARMACEUTICALS, INC.	28 Jul 2001	Pending
2002080144	WANTON PHARMACEUTICALS, INC.	28 Jul 2001	5	Pharmaceutical preparations; medicaments.	WANTON PHARMACEUTICALS, INC.	28 Jul 2001	Pending
2002080145	WANTON PHARMACEUTICALS, INC.	28 Jul 2001	5	Pharmaceutical preparations; medicaments.	WANTON PHARMACEUTICALS, INC.	28 Jul 2001	Pending
2002080146	WANTON PHARMACEUTICALS, INC.	28 Jul 2001	5	Pharmaceutical preparations; medicaments.	WANTON PHARMACEUTICALS, INC.	28 Jul 2001	Pending
2002080147	WANTON PHARMACEUTICALS, INC.	28 Jul 2001	5	Pharmaceutical preparations; medicaments.	WANTON PHARMACEUTICALS, INC.	28 Jul 2001	Pending
2002080148	WANTON PHARMACEUTICALS, INC.	28 Jul 2001	5	Pharmaceutical preparations; medicaments.	WANTON PHARMACEUTICALS, INC.	28 Jul 2001	Pending
2002080149	WANTON PHARMACEUTICALS, INC.	28 Jul 2001	5	Pharmaceutical preparations; medicaments.	WANTON PHARMACEUTICALS, INC.	28 Jul 2001	Pending
2002080150	WANTON PHARMACEUTICALS, INC.	28 Jul 2001	5	Pharmaceutical preparations; medicaments.	WANTON PHARMACEUTICALS, INC.	28 Jul 2001	Pending









	MURKIN (MUR) DIRECTOR (MUR)	Kerman	23 May 2020 13:26:53	National Police	Registered	23 May 2020
	MURKIN (MUR) DIRECTOR (MUR)	Kerman	23 May 2020 13:26:53	National Police	Registered	23 May 2020
	MURKIN (MUR) DIRECTOR (MUR)	Kerman	23 May 2020 13:26:53	National Police	Registered	23 May 2020
	MURKIN (MUR) DIRECTOR (MUR)	Kerman	23 May 2020 13:26:53	National Police	Registered	23 May 2020
	MURKIN (MUR) DIRECTOR (MUR)	Kerman	23 May 2020 13:26:53	National Police	Registered	23 May 2020
	MURKIN (MUR) DIRECTOR (MUR)	Kerman	23 May 2020 13:26:53	National Police	Registered	23 May 2020
	MURKIN (MUR) DIRECTOR (MUR)	Kerman	23 May 2020 13:26:53	National Police	Registered	23 May 2020







2008A (RND)  
DANCEY (RNDW)

21 JAN 2020 15:53:53

17 AUG 2020 16:29:39

21 JAN 2020 15:53:53

Notified

Registered

05

05: International Registration

Notified No (199)

21 JAN 2020



2008A (RND)  
DANCEY (RNDW)

21 JAN 2020 15:53:53

17 AUG 2020 16:29:39

21 JAN 2020 15:53:53

Notified

Registered

05

05: International Registration

Notified No (199)

21 JAN 2020



2008A (RND)  
DANCEY (RNDW)

21 JAN 2020 15:53:53

17 AUG 2020 16:29:39

29 JAN 2020 15:53:53

Notified

Registered

05

05: International Registration

Notified No (199)

29 JAN 2020



2008A (RND)  
DANCEY (RNDW)

16 JUN 2020 15:53:53

17 AUG 2020 16:29:39

16 JUN 2020 15:53:53

Notified

Registered

05

05: International Registration

Notified No (199)

16 JUN 2020



2008A (RND)  
DANCEY (RNDW)

Business Record

17 AUG 2020 16:29:39

17 SEP 2020 16:58:57

Notified

Registered

05

05: International Registration

Notified No (199)

17 SEP 2020



2008A (RND)  
DANCEY (RNDW)

17 AUG 2020 16:29:39

17 AUG 2020 16:29:39

29 JAN 2020 15:53:53

Notified

Registered

05

05: International Registration

Notified No (199)

29 JAN 2020



2008A (RND)  
DANCEY (RNDW)

17 AUG 2020 16:29:39

17 AUG 2020 16:29:39

29 JAN 2020 15:53:53

Notified

Registered

05

05: International Registration

Notified No (199)

29 JAN 2020



2008A (RND)  
DANCEY (RNDW)

17 AUG 2020 16:29:39

17 AUG 2020 16:29:39

29 JAN 2020 15:53:53

Notified

Registered

05


05: International Registration

Notified No (199)

29 JAN 2020







UNITED STATES PATENT AND TRADEMARK OFFICE

CLASSIFICATION

CLASS

PHARMACEUTICAL PREPARATION FOR THE PREVENTION AND TREATMENT OF ALLERGIC REACTIONS

PHARMACEUTICAL PREPARATION FOR THE PREVENTION AND TREATMENT OF ALLERGIC REACTIONS

PHARMACEUTICAL PREPARATION FOR THE PREVENTION AND TREATMENT OF ALLERGIC REACTIONS

PHARMACEUTICAL PREPARATION FOR THE PREVENTION AND TREATMENT OF ALLERGIC REACTIONS

PHARMACEUTICAL PREPARATION FOR THE PREVENTION AND TREATMENT OF ALLERGIC REACTIONS

PHARMACEUTICAL PREPARATION FOR THE PREVENTION AND TREATMENT OF ALLERGIC REACTIONS





Class	Priority	Inventors	Applicant	Title	Pub. No.	Pub. Date	Pub. No.	Pub. Date	Pub. No.	Pub. Date	Pub. No.	Pub. Date
28	17 Mar 2009	HONG SEUNG	HONG SEUNG	Method of providing eye disease information about eye disease and the treatment thereof	20090131546	27 Jun 2009	20090131546	27 Jun 2009	20090131546	27 Jun 2009	20090131546	27 Jun 2009
28	17 Mar 2009	HONG SEUNG	HONG SEUNG	Method of providing eye disease information about eye disease and the treatment thereof	20090131546	27 Jun 2009	20090131546	27 Jun 2009	20090131546	27 Jun 2009	20090131546	27 Jun 2009
28	17 Mar 2009	HONG SEUNG	HONG SEUNG	Method of providing eye disease information about eye disease and the treatment thereof	20090131546	27 Jun 2009	20090131546	27 Jun 2009	20090131546	27 Jun 2009	20090131546	27 Jun 2009
28	17 Mar 2009	HONG SEUNG	HONG SEUNG	Method of providing eye disease information about eye disease and the treatment thereof	20090131546	27 Jun 2009	20090131546	27 Jun 2009	20090131546	27 Jun 2009	20090131546	27 Jun 2009
28	17 Mar 2009	HONG SEUNG	HONG SEUNG	Method of providing eye disease information about eye disease and the treatment thereof	20090131546	27 Jun 2009	20090131546	27 Jun 2009	20090131546	27 Jun 2009	20090131546	27 Jun 2009
28	17 Mar 2009	HONG SEUNG	HONG SEUNG	Method of providing eye disease information about eye disease and the treatment thereof	20090131546	27 Jun 2009	20090131546	27 Jun 2009	20090131546	27 Jun 2009	20090131546	27 Jun 2009
28	17 Mar 2009	HONG SEUNG	HONG SEUNG	Method of providing eye disease information about eye disease and the treatment thereof	20090131546	27 Jun 2009	20090131546	27 Jun 2009	20090131546	27 Jun 2009	20090131546	27 Jun 2009
28	17 Mar 2009	HONG SEUNG	HONG SEUNG	Method of providing eye disease information about eye disease and the treatment thereof	20090131546	27 Jun 2009	20090131546	27 Jun 2009	20090131546	27 Jun 2009	20090131546	27 Jun 2009
28	17 Mar 2009	HONG SEUNG	HONG SEUNG	Method of providing eye disease information about eye disease and the treatment thereof	20090131546	27 Jun 2009	20090131546	27 Jun 2009	20090131546	27 Jun 2009	20090131546	27 Jun 2009
28	17 Mar 2009	HONG SEUNG	HONG SEUNG	Method of providing eye disease information about eye disease and the treatment thereof	20090131546	27 Jun 2009	20090131546	27 Jun 2009	20090131546	27 Jun 2009	20090131546	27 Jun 2009





05 - New central preparations

18 Mar 2008 13:59:02

Registered

35

05 - New central preparations

Receipt No. (35)

18 Mar 2008

05 - New central preparations

18 Mar 2008 13:59:02

Registered

07

05 - New central preparations

Receipt No. (36)

18 Mar 2008

05 - New central preparations

18 Mar 2008 13:59:02

Registered

07

05 - New central preparations

Receipt No. (37)

18 Mar 2008

05 - New central preparations

18 Mar 2008 13:59:02

Registered

07

05 - New central preparations

Receipt No. (38)

18 Mar 2008

05 - New central preparations

18 Mar 2008 13:59:02

Registered

07

05 - New central preparations

Receipt No. (39)

18 Mar 2008

05 - New central preparations

18 Mar 2008 13:59:02

Registered

07

05 - New central preparations

Receipt No. (40)

18 Mar 2008

05 - New central preparations

18 Mar 2008 13:59:02

Registered

07

05 - New central preparations

Receipt No. (41)

18 Mar 2008

05 - New central preparations

18 Mar 2008 13:59:02

Registered

07

05 - New central preparations

Receipt No. (42)

18 Mar 2008

05 - New central preparations

05 - New central preparations







Pub. No.	Pub. Date	Pub. Title	Pub. No.	Pub. Date	Pub. Title	Pub. No.	Pub. Date	Pub. Title	Pub. No.	Pub. Date
0000000000000000			0000000000000000			0000000000000000			0000000000000000	
0000000000000000	13 MAR 2020	13 MAR 2020	0000000000000000	13 MAR 2020	13 MAR 2020	0000000000000000	13 MAR 2020	13 MAR 2020	0000000000000000	13 MAR 2020
0000000000000000	13 MAR 2020	13 MAR 2020	0000000000000000	13 MAR 2020	13 MAR 2020	0000000000000000	13 MAR 2020	13 MAR 2020	0000000000000000	13 MAR 2020
0000000000000000	13 MAR 2020	13 MAR 2020	0000000000000000	13 MAR 2020	13 MAR 2020	0000000000000000	13 MAR 2020	13 MAR 2020	0000000000000000	13 MAR 2020
0000000000000000	13 MAR 2020	13 MAR 2020	0000000000000000	13 MAR 2020	13 MAR 2020	0000000000000000	13 MAR 2020	13 MAR 2020	0000000000000000	13 MAR 2020


25: For oral, pharmaceutical preparation for the treatment of ...  
26: For oral, pharmaceutical preparation for the treatment of ...  
27: For oral, pharmaceutical preparation for the treatment of ...  
28: For oral, pharmaceutical preparation for the treatment of ...

In witness whereof, this Act was signed by the persons appeared after reading and approval, whereupon I, the Notary Public, also signed the same, affixing my official seal.


Basel, Switzerland, September 29<sup>th</sup> (twenty-ninth) 2023 (two thousand and twenty-three)

  
Isabelle Andrea Schubert Santana

  
Robert Carroll Stanley

  
Andrea Schmutz, Notary Public

Allg. Reg. 2023/no. 194



### APOSTILLE

(Convention de la Haye du 5 octobre 1961)

1. Country **Swiss Confederation, Canton of Basel-City**  
Land **Schweizerische Eidgenossenschaft, Kanton Basel-Stadt**

This public document  
Diese öffentliche Urkunde

2. has been signed by **lic. iur. Andrea Schmutz**  
ist unterschrieben von
3. acting in the capacity of **Notary Public**  
in seiner Eigenschaft als
4. bears the stamp/seal of **Schmutz Andrea**  
Sie ist versehen mit dem  
Stempel/Siegel des/der

Certified / Bestätigt

5. at / in **Basel** 6. the / am **29.09.2023**
7. by the **Legalisation Office of the Canton of Basel-City**  
durch das **Beglaubigungsbüro des Kantons Basel-Stadt**
8. No. / Nr. **261586** tax / Taxe **CHF 20.00**
9. stamp/seal **LEGALISATION**  
Stempel/Siegel
10. Signature **Fabio Marzo**  
Unterschrift

